IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Files An 8-K Other Events
Item 8.01. Other Events.

On June 18, 2018, Immune Design Corp. (the “Company”) commenced a tender offer to exchange eligible stock options for replacement stock options with modified terms, to the Offer to Exchange Eligible Options for New Options, dated June 18, 2018, as amended (the “Exchange Offer”). The Exchange Offer expired at 6:00 p.m., Pacific Time, on Tuesday, July17, 2018.

to the Exchange Offer, 31 employees elected to exchange outstanding stock options, and the Company accepted for cancellation, stock options to purchase an aggregate of 1,590,083 shares of the Company’s common stock (“Common Stock”), representing approximately 65% of the total shares of Common Stock underlying the stock options eligible for exchange. On July17, 2018, immediately following the expiration of the Exchange Offer, the Company granted new stock options to purchase 962,099 shares of Common Stock, to the terms of the Exchange Offer and the Company’s 2014 Omnibus Incentive Plan. The exercise price per share of the stock options granted to the Exchange Offer was $4.40 per share, which is the closing price per share of Common Stock on The Nasdaq Global Market on the grant date of the stock options. The vesting terms of the new stock options are described in detail in the Exchange Offer.

About IMMUNE DESIGN CORP. (NASDAQ:IMDZ)

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA).